Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). - Wikidata - awgldk - TriplyDB

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

http://www.wikidata.org/entity/Q30993164

about

Interventions for renal vasculitis in adults Interventions for renal vasculitis in adults Immunosuppressive treatment for non-systemic vasculitic neuropathy Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Causal attributions about disease onset and relapse in patients with systemic vasculitis.Health-related quality of life for patients with vasculitis and their spouses.Clinically Apparent Arterial Thrombosis in Persons with Systemic Vasculitis.Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis Vasculitis: lessons learned.An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis Prediction of response to treatment by gene expression profiling of peripheral blood in patients with microscopic polyangiitis.Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab versus cyclophosphamide for ANCA-associated vasculitis.Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).Development of comprehensive disease assessment in systemic vasculitis.Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis Notes on the kidney and its diseases for the neurologist.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines Pulmonary-renal syndromes.Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission.Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index Assessment of damage in vasculitis: expert ratings of damage.Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.Pulmonary vasculitis in the intensive care unit.Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.Damage assessment in ANCA-associated vasculitis.Impact of rituximab trials on the treatment of ANCA-associated vasculitis.The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis.Examining the relationship between fatigue and cognition after stroke: A systematic review.

P2860

Q24187038-729B6A7A-0887-46D1-BD58-8C181BB79E99 Q24242768-4A959B1E-1A81-45D8-8C72-6A1198B5533C Q24246358-31813710-C774-4EF7-9A26-F3712BC18D3F Q30696868-825F59F1-DF6F-4642-A8B3-78CBE51DF9C0 Q30849537-DEBD80A9-68D3-42B8-9B48-400628186F9C Q33560905-928BE7C0-2E25-4D16-87D7-A06B68EDBB69 Q33731434-76AEF51C-0A4D-4634-9324-753D390A2C1E Q33872858-0DC4DA42-3369-45CC-918B-B75F363F806D Q33921278-6A44FF9A-7E7B-4D13-BBFA-5F958334F92F Q33957204-F8E9CB18-5C8F-4961-AF9D-711BB63831B3 Q34111969-E08CE582-65D7-4F00-8F84-D0C2510CBD22 Q34157764-5BE75A19-A5DE-41F6-9F27-EB99BD2D3D3A Q34730043-28241E2A-96AB-4DB1-9F83-304C93350BDF Q35082362-8DE7502D-4265-43FC-AC11-EF6272C924D1 Q35109118-EC0D1568-E1A4-4CA1-84F5-E4430CC743D9 Q35114049-7A9239DB-E734-498F-80C4-4F85C04893E2 Q35124613-3FC48669-3059-4CE8-A05F-3B4678B3F84C Q35649141-76E57FA4-48D1-413C-BC4F-6E6F332C0D8B Q35759939-99A9E9A0-AC4D-4C14-975B-6316DDE2A28D Q35861668-D04B4309-45C2-42AC-A39A-95D90D96D0BA Q35868276-57D311FB-942A-40AC-8F01-E44C920D351D Q35878676-61120F65-7BE5-4EBD-A31C-EF851FE8571B Q36227382-536A8867-6133-405D-A41C-935A08AA0AB2 Q36684589-FCB351E8-E179-48D2-8172-4CFFF4607BE4 Q36715376-F20FF959-7820-47BD-BFA6-B2101773C948 Q36724093-6AC58BA6-F2A8-4985-A135-CF391E99ECA0 Q36839521-8D5D38F0-20E8-4098-BB0A-30B91213CC91 Q36843060-28D737E4-782D-4725-839D-2F12B25EB167 Q36916710-04B92090-92F2-4997-BA2B-F45FE8BE91EE Q37006816-00207D77-4AB8-4A26-AD83-E555B6AF2850 Q37031689-2F9CCFDF-284C-4DCD-AE26-83EB525B6FFF Q37170449-A969429C-FCA4-46BC-8F1D-960CC91ED55B Q37294542-9F82B88C-611F-4F30-BD16-1BBA96839377 Q37686029-14B481EC-863C-4B01-93AF-E8779CB2776C Q37861390-A2D10427-23EF-4F10-8508-74A90B1C5039 Q37926278-46CFE711-3439-44C2-A2B2-93D3C6A6316D Q38043946-4C79A1F1-3738-4A03-99AB-566C5267C7C5 Q38152651-9B468A65-64E8-4F4C-9BFA-90B05C5CBCF6 Q38512570-72ACC9D6-2FC8-4413-AEAA-B05A5E2444F5 Q38703444-BF2682C1-F12E-4A6F-9E7A-996DEBACDDFD

P2860

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

http://www.wikidata.org/entity/Q30993164

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@ast

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@en

type

label

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@ast

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@en

prefLabel

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@ast

Damage caused by Wegener's gra ...... tosis Etanercept Trial (WGET).

@en

P1433

Q30993164-72A55D9C-7440-4489-8742-D4F6FF65B187

P1476

Q30993164-DCF0E6B1-2BAE-40DB-9515-58C0EC473F98

P2093

Q30993164-23681A96-E32E-4E9F-AAFA-5E9F2ABF69BC

Q30993164-3347E042-3F78-4C61-82B7-6FED5E1CD707

Q30993164-3D1C1D86-4532-4C27-ACAA-30295E010F62

Q30993164-685C55A2-0DAA-46F1-B282-4E621AC21AD5

Q30993164-93743437-759B-40F8-BD3F-78766C3FC194

Q30993164-A64B337C-01E3-4A39-9751-75AB25620C8E

Q30993164-B2653AF6-CBA1-4330-991E-7BD6C4B3F940

Q30993164-C04EAEC8-B2FB-4FF6-B9E9-8632EE2EC3C8

Q30993164-D4A095A6-4D7E-40C7-9C20-284344D3EE31

Q30993164-D9292387-C534-4560-BBCA-B18655F81983

P2860

Q30993164-90AEAAF9-E6AD-490D-91EF-B558A425AB3B

P304

Q30993164-89FDFC28-2B65-4F15-BF2D-3BB1086517A7

P31

Q30993164-98285E97-F371-4235-8D9C-020ACAD34B87

P356

Q30993164-E96FC366-1197-4A9F-BDB8-44F245A49EF0

P433

Q30993164-46961652-B6C6-4826-BA04-219E336D99A5

P478

Q30993164-F2B67A2E-7A7B-4E50-B598-7B89E1179513

P50

Q30993164-1D6FA3ED-5D66-4962-AF30-9AC9756D1B93

Q30993164-76B0343F-C977-4FBA-A75A-F8212C40BB7F

Q30993164-A4B97E00-09CD-4C51-BD2A-7B8F6561F2C7

P577

Q30993164-038A2389-7537-499A-8985-FBE5CE1F102F

P5875

Q30993164-8A4C0C81-C1CD-474B-95DF-2FFF6288650D

P698

Q30993164-2AE9CB90-D276-4D33-8761-8E84836DC085

P356

P1433

Arthritis and Rheumatism

P1476

Damage caused by Wegener's gra ...... atosis Etanercept Trial (WGET)

@en

P2093

E William St Clair

http://www.w3.org/2001/XMLSchema#string

Gary S Hoffman

http://www.w3.org/2001/XMLSchema#string

Janet T Holbrook

http://www.w3.org/2001/XMLSchema#string

John C Davis

http://www.w3.org/2001/XMLSchema#string

John H Stone

http://www.w3.org/2001/XMLSchema#string

Nancy B Allen

http://www.w3.org/2001/XMLSchema#string

Peter A Merkel

http://www.w3.org/2001/XMLSchema#string

Robert Spiera

http://www.w3.org/2001/XMLSchema#string

Steven R Ytterberg

http://www.w3.org/2001/XMLSchema#string

Ulrich Specks

http://www.w3.org/2001/XMLSchema#string

P2860

Wegener granulomatosis: an analysis of 158 patients.

P304

2168-2178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.21117

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Raashid Ahmed Luqmani

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7758275

http://www.w3.org/2001/XMLSchema#string

P698

15986348

http://www.w3.org/2001/XMLSchema#string